乐普LEPU品牌怎么样 申请店铺

我要投票 乐普LEPU在医疗器械行业中的票数:255 更新时间:2025-04-07
乐普LEPU是哪个国家的品牌?「乐普LEPU」是乐普(北京)医疗器械股份有限公司旗下著名品牌。该品牌发源于北京市,由创始人蒲忠杰在1999-06-11期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力乐普LEPU品牌出海!通过在本页面挂载乐普LEPU品牌的产品链接和联系邮箱,可以提高乐普LEPU产品曝光!跨境电商爆单神器,目前只要100元/年哦~

乐普LEPU怎么样

创立于1999年,集产品研发、生产、销售于一体,专业从事植介入诊疗器械及设备领域的医疗产品产业集团,其心血管病植介入诊疗器械在业内颇具影响力

乐普(北京)医疗器械股份有限公司(简称乐普医疗集团)创立于1999年,股份制集团上市公司(股票代码300003),公司销售网络遍布全中国及95个国家和地区,年营业收入46亿元人民币。 通过坚持技术创新、合作共赢的发展之路,乐普医疗集团正努力建立四位一体的心血管全产业链平台型企业。

乐普(北京)医疗器械股份有限公司创立于1999年,总部位于北京市中关村科技园区昌平园。公司是从事冠状动脉药物支架、先心封堵器、心脏瓣膜、造影机等心血管疾病植介入诊疗器械及设备产品研发、生产与销售的中外合资央企控股企业,是2009年在深交所创业板上市的28家企业之一。公司目前拥有国内外8家子公司,产品临床应用覆盖全国1200家以上心脏诊疗中心,已发展成为国内从事的心血管病植介入诊疗器械与设备的医疗产品产业集团。

乐普公司集合了材料、机械、电子、精密加工、临床医学等各类专业人才,拥有一支在产品研发、质量控制、临床验证、市场开拓、企业管理等方面专业的经验丰富的人才队伍。研制开发涵盖:冠心病、结构性心脏病、心脏节律、预先和术后诊断及诊疗设备五大领域的植介入产品,取得了一系列具有国内、国际水平的研究成果。是国内规模较大的也是拥有多种技术特点药物支架产品的制造企业,是亚洲较大的人工心脏瓣膜制造企业,是国内心脏起搏器的先行者,是国内心脏封堵器、血管造影机的市场佼佼者,是国内研制肾动脉射频消融导管的企业。

乐普公司疗创立以来,先后承担了国家发改委高技术产业化示范工程项目、国家科技部863计划发展项目、科技支撑计划项目等几十项国家重大课题。2013年,以乐普公司为依托单位,组建了“国家心脏病植介入诊疗器械及设备工程技术研究中心”,将进一步推动建设国家心脏病植介入诊疗器械及设备技术创新、产业化和人才聚集的平台,攻克一系列行业发展的核心技术和核心工艺,推动我国心脏病植介入医疗事业的迅速发展。我们秉承“以科技的力量,从心点燃生命的光辉”,为广大医护工作者提供更好更强的医疗产品与技术,使更多心血管病患者能够用得上用得起中国自己的医疗技术和产品。


Founded in 1999, it is a medical product industry group integrating product R & D, production and sales, specializing in the field of interventional devices and equipment. Its cardiovascular interventional devices have great influence in the industry. Lepu (Beijing) Medical Devices Co., Ltd. (referred to as Lepu medical group) was founded in 1999. The joint stock group listed company (Stock Code: 300003) )The company's sales network covers all over China and 95 countries and regions, with an annual operating revenue of 4.6 billion yuan. By adhering to the development path of technological innovation and win-win cooperation, Lepu medical group is striving to establish a platform enterprise of four in one cardiovascular industry chain. Lepu (Beijing) medical equipment Co., Ltd. was founded in 1999 and its headquarter is located in Changping Park, Zhongguancun Science and Technology Park, Beijing. The company is a Sino foreign joint-venture state-owned enterprise holding the R & D, production and sales of cardiovascular disease interventional devices and equipment products, such as coronary drug stent, precordial occluder, heart valve and contrast machine. It is one of the 28 enterprises listed on the growth enterprise market of Shenzhen Stock Exchange in 2009. At present, the company has 8 subsidiaries at home and abroad, with clinical application covering more than 1200 cardiac diagnosis and treatment centers across the country, and has developed into a domestic medical product industry group engaged in cardiovascular interventional diagnosis and treatment equipment and equipment. Lepu company has gathered all kinds of professional talents in materials, machinery, electronics, precision processing, clinical medicine, etc., and has a professional team with rich experience in product research and development, quality control, clinical verification, market development, enterprise management, etc. The research and development covers five fields: coronary heart disease, structural heart disease, heart rhythm, pre and post-operative diagnosis and treatment equipment, and a series of research results with domestic and international level have been achieved. It is a large-scale manufacturing enterprise with a variety of technical characteristics of drug stent products in China, a large artificial heart valve manufacturing enterprise in Asia, a pioneer in domestic cardiac pacemaker, a market leader in domestic cardiac occluder and angiograph, and a domestic enterprise in the research and development of renal artery radiofrequency catheter ablation. Since its establishment, Lepu company has successively undertaken dozens of national major projects, such as the high-tech industrialization demonstration project of the national development and Reform Commission, the 863 program development project of the Ministry of science and technology, and the science and technology support program project. In 2013, with Lepu company as the supporting unit, the "National Center for engineering and technology research of heart disease plant intervention diagnosis and treatment equipment and equipment" was established, which will further promote the construction of a national platform for innovation, industrialization and talent accumulation of heart disease plant intervention diagnosis and treatment equipment and equipment, attack a series of core technologies and core processes for industry development, and promote China's heart disease plant intervention medical affairs The rapid development of the industry. We adhere to the principle of "lighting up the brilliance of life from the heart with the power of science and technology" to provide better and stronger medical products and technologies for medical workers, so that more patients with cardiovascular diseases can use their own medical technologies and products in China.

本文链接: https://brand.waitui.com/56660df8a.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

耐克等品牌或将被迫提价

根据特朗普4月2日公布的关税清单,美国将对柬埔寨、越南、泰国等多个国家加征30%以上的对等关税,作为全球供应链上的重要一环,这些国家面临巨大的冲击。越南纺织服装协会的数据显示,2024年越南纺织品服装出口额达440亿美元,美国是其最大市场,耐克等服装品牌超过35%的产能聚集在越南。随着美国所谓“对等关税”措施即将实施,这些服装品牌将被迫提价。(央视财经)

2小时前

2025清明档新片总票房破3亿元

36氪获悉,据猫眼专业版数据,2025年4月6日17时20分,2025年清明档新片总票房破3亿元,《我的世界大电影》持续领跑,《向阳·花》《不说话的爱》分列二三位。

2小时前

紫金矿业:出售资产完成交割

36氪获悉,紫金矿业公告,公司澳大利亚全资子公司诺顿金田已收到现金1.56亿澳元及价值1000万澳元的8333万股MI6股票,交易已正式完成交割。标的公司持有BAB项目100%权益,截至2024年末,BAB项目拥有资源量金72吨,平均品位1.2克/吨。2014年9月,诺顿金田以约2500万美元对价收购标的公司100%股权。

2小时前

深交所公示第二届上市委、重组委委员候选人名单

36氪获悉,深圳证券交易所4月6日发布公告,日前,深交所启动了第二届上市审核委员会、第二届并购重组审核委员会组建工作。经相关单位推荐、履行相关程序,形成上市委、重组委委员候选人名单。为强化社会监督,保障上市委、重组委选聘工作公开、公平、公正,现就委员候选人名单予以公示,公示期为5个工作日。

2小时前

上交所公示第二届上市委、重组委委员候选人名单

36氪获悉,上海证券交易所发布公告,日前,上交所启动了第二届上市审核委员会、第二届并购重组审核委员会组建工作。经相关单位推荐、履行相关程序,形成上市委、重组委委员候选人名单。为强化社会监督,保障上市委、重组委选聘工作公开、公平、公正,现就委员候选人名单予以公示,公示期为5个工作日。

2小时前

本页详细列出关于仁和可立克的品牌信息,含品牌所属公司介绍,仁和可立克所处行业的品牌地位及优势。
咨询